ArticleESMO real world data and digital oncology2025
Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Altered mental status in cancer-related emergency hospitalizations: prevalence and recorded reasons for admission.BMC emergency medicine · 2026Article
- Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: No direct comparative study has evaluated first-line immunomonotherapy and immunochemotherapy regimens for advanced non-small-cell lung cancer (NSCLC), and this poses a significant challenge to selecting an optimal treatment regimen in clinical practice. The objective of this study was to compare the effectiveness of first-line immunomonotherapy and immunochemotherapy regimens in advanced NSCLC with a focus on the time to next treatment (TTNT) and overall survival (OS). Patients and methods: This retrospective, multicenter cohort study conducted at 68 hospitals of the Council for Coordination of Designated Cancer Care Hospitals in Osaka Prefecture, Japan included patients with advanced NSCLC who had received immunomonotherapy or immunochemotherapy as the initial treatment between January 2019 and December 2021. Data were collected from the cancer registry database and administrative data in which these hospitals participate. The median follow-up duration was 8.8 months (interquartile range 4.7-14.0 months). Exposure was first-line immunomonotherapy or immunochemotherapy. The endpoint was the comparison of OS and TTNT among immunomonotherapy or immunochemotherapy regimens; atezolizumab-chemotherapy (ATZ-chemo), pembrolizumab-chemotherapy (Pembro-chemo), and nivolumab-ipilimumab-chemotherapy (NIV + IPI-chemo) regimens were further compared. Participants' baseline characteristics (e.g. age at diagnosis, sex, histological tumor type, stage, Barthel index, smoking status, body mass index, and treatment type) were obtained and propensity score-matched analyses were carried out. Results: We identified 2101 patients with stage IV NSCLC who received first-line treatment with ATZ, Pembro, or NIV + IPI). After propensity score matching, the comparison of immunomonotherapy and immunochemotherapy regimens showed no significant difference in TTNT (median: 8.1 versus 7.7 months, Conclusions: Our investigation suggested that compared with immunomonotherapy regimens, immunochemotherapy regimens might contribute more to prolonged survival than immunomonotherapy regimens, and that pembrolizumab-containing regimens might be more beneficial for extending prognosis compared with atezolizumab-containing regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.